Material and Methods:
The Epley Omniax (Figure 1 ) is a clinically approved medical device conventionally used in balance disorder therapy, and can rotate 360 degrees around each axis. We used this device to test patient tolerance to slow, single arc rotation. Each patient underwent slow, single arc rotation in two orientations; sitting and lying. Patients were rotated a full 360 degrees in increments of 45 degrees. The rotation was paused for 30 seconds at each 45 degree increment to simulate beam delivery; in total this simulates the delivery of 8 beams. Patients were rotated in both an upright (sitting) and lying position in the same session. Response was monitored via validated psychometric questionnaires for claustrophobia, anxiety, and motion sickness. Thus far, 10 of a planned 15 current or former cancer patients have been recruited.
Results:
Patient tolerance has been high -9 out of 10 have completed the study without incident, and in general patient feedback has been positive. One patient was unable to complete the lying rotation, but was still able to complete the sitting rotation without issue. No detectible differences in anxiety or motion sickness have been observed from either sitting or lying rotation. A summary of the patient cohort and results thus far is outlined in table 1. Accrual for this study is ongoing.
Conclusion:
Patient rotation could enable much simpler treatment for both conventional and advanced treatmentshowever, it is often assumed that patient tolerance to rotation would be very low. The results generated thus far show that there is at least a cohort of patients who would find slow rotation an acceptable therapeutic intervention.
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Abstract withdrawn Purpose or Objective: Potential severe or lethal toxicity in regards to dose escalation of locally-advanced NSCLC patients calls for caution. A national quality assurance program was conducted over a period of three years in Denmark in order to prepare for the heterogeneous FDG-guided dose escalation phase 3 trial: NARLAL2.
Material and Methods:
A national work group consisting of clinical oncologists and medical physicists was established. Different workshops were conducted in order to standardise 1) delineation of organs at risk (OAR) and target, 2) PET determination, 3) treatment planning, and 4) IGRT and adaptive strategy. In the standard arm, the planning target volume (PTV) is prescribed a homogeneous mean dose of 66 Gy / 33 fractions (fr). For the experimental arm, the mean dose is heterogeneously escalated up to 95 Gy / 33 fr for the most FDG-PET active part of the primary tumour and 74 Gy / 33fr for malignant lymph nodes ≥ 4 cc. The escalation is always limited in favour of OAR constraints. Dose constraints were added to reduce the risk of severe complications. Besides the traditional spinal cord, heart and oesophagus delineations, thorax wall, aorta, bronchi, trachea, and connective tissue (here defined as any remaining voxels in mediastinum not included in other OARs or GTV) were delineated. A maximum dose of D1cc < 74 Gy for these OARs was chosen as safe dose constraints (D1cc < 70 Gy for oesophagus). An online catalogue with examples of such delineations was created for oncologists. The randomisation is performed when both the standard and escalated plans are clinically accepted. The two treatment plans, delineations and images are prospectively exported to a national database, which requires a consistent naming convention for delineations within each centre. Endpoint of trial is local control and the standard procedure for suspicion of tumour recurrence is biopsy. For cases where biopsy is not applicable, a central committee has been established to evaluate each case. Blood samples are obtained during the treatment course for future examination.
